Advertisement
Research Article Pharmaceutics, Drug Delivery and Pharmaceutical Technology| Volume 108, ISSUE 6, P2119-2127, June 01, 2019

Prediction of Dissolution Profiles From Process Parameters, Formulation, and Spectroscopic Measurements

Published:February 08, 2019DOI:https://doi.org/10.1016/j.xphs.2019.01.023

      Abstract

      This study utilized multiple modeling approaches to predict immediate release tablet dissolution profiles of 2 model drugs: theophylline and carbamazepine. Two sets of designs of experiments were applied based on individual drug characteristics to build in adequate dissolution variability. The tablets were scanned using a near-infrared (NIR) spectrometer and then subjected to in vitro dissolution test at critical time points. Because of the inherent difference in dissolution profiles, a hierarchical modeling approach was applied for theophylline data, whereas global models were constructed from carbamazepine data. The partial least squares models were trained using 3 predictor sets including (1) formulation, material, and process variables, (2) NIR spectra, and (3) a combination of both. The dependent variables of the models were the dissolution profiles, which were presented either as parameters of Weibull fitting curves or raw data. The comparison among the predictive models revealed that the incorporation of NIR spectral information in calibration reduced prediction error in the carbamazepine case but undermined the performance of theophylline models. It suggests that the modeling strategy for dissolution prediction of pharmaceutical tablets should not be universal but on a case-by-case basis.

      Keywords

      To read this article in full you will need to make a payment
      APhA Member Login
      APhA Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tabasi S.H.
        • Moolchandani V.
        • Fahmy R.
        • Hoag S.W.
        Sustained release dosage forms dissolution behavior prediction: a study of matrix tablets using NIR spectroscopy.
        Int J Pharm. 2009; 382: 1-6
        • Freitas M.P.
        • Sabadin A.
        • Silva L.M.
        • et al.
        Prediction of drug dissolution profiles from tablets using NIR diffuse reflectance spectroscopy: a rapid and nondestructive method.
        J Pharm Biomed Anal. 2005; 39: 17-21
        • Hernandez E.
        • Pawar P.
        • Keyvan G.
        • et al.
        Prediction of dissolution profiles by non-destructive near infrared spectroscopy in tablets subjected to different levels of strain.
        J Pharm Biomed Anal. 2016; 117: 568-576
        • Zhu Z.
        • Yang T.
        • Zhao Y.
        • Gao N.
        • Leng D.
        • Ding P.
        A simple method to improve the dissolution of repaglinide and exploration of its mechanism.
        Asian J Pharm Sci. 2014; 9: 218-225
        • Kamalakkannan V.
        • Puratchikody A.
        • Ramanathan L.
        • Jayapraba S.
        Development and validation of a dissolution test with reversed-phase high performance liquid chromatographic analysis for Candesartan cilexetil in tablet dosage forms.
        Arab J Chem. 2016; 9: S867-S873
        • Myerson A.S.
        • Krumme M.
        • Nasr M.
        • Thomas H.
        • Braatz R.D.
        Control systems engineering in continuous pharmaceutical manufacturing May 20–21, 2014 continuous manufacturing symposium.
        J Pharm Sci. 2015; 104: 832-839
        • Zannikos P.N.
        • Li W.-I.
        • Drennen J.K.
        • Lodder R.A.
        Spectrophotometric prediction of the dissolution rate of carbamazepine tablets.
        Pharm Res. 1991; 8: 974-978
        • Donoso M.
        • Ghaly E.S.
        Prediction of drug dissolution from tablets using near-infrared diffuse reflectance spectroscopy as a nondestructive method.
        Pharm Dev Technol. 2005; 9: 247-263
        • Blanco M.
        • Alcala M.
        • Gonzalez J.M.
        • Torras E.
        Determination of dissolution profiles in intact pharmaceutical tablets by NIR spectroscopy.
        J Process Anal Technol. 2006; 3: 25-28
        • Abe H.
        • Otsuka M.
        Effects of lubricant-mixing time on prolongation of dissolution time and its prediction by measuring near infrared spectra from tablets.
        Drug Dev Ind Pharm. 2012; 38: 412-419
        • Markl D.
        • Zeitler J.A.
        A review of disintegration mechanisms and measurement techniques.
        Pharm Res. 2017; 34: 890-917
        • Marais A.F.
        • Song M.
        • de Villiers M.M.
        Effect of compression force, humidity and disintegrant concentration on the disintegration and dissolution of directly compressed furosemide tablets using croscarmellose sodium as disintegrant.
        Trop J Pharm Res. 2003; 2: 125-135
        • Patel S.
        • Kaushal A.M.
        • Bansal A.K.
        Compression physics in the formulation development of tablets.
        Crit Rev Ther Drug Carrier Syst. 2006; 23: 1-65
        • Peng Y.
        • Geraldrajan M.
        • Chen Q.
        • Sun Y.
        • Johnson J.R.
        • Shukla A.J.
        Prediction of dissolution profiles of acetaminophen beads using artificial neural networks.
        Pharm Dev Technol. 2006; 11: 337-349
        • Sathe P.M.
        • Venitz J.
        Comparison of neural network and multiple linear regression as dissolution predictors.
        Drug Dev Ind Pharm. 2003; 29: 349-355
        • Tinke A.
        • Vanhoutte K.
        • De Maesschalck R.
        • Verheyen S.
        • De Winter H.
        A new approach in the prediction of the dissolution behavior of suspended particles by means of their particle size distribution.
        J Pharm Biomed Anal. 2005; 39: 900-907
        • Rantanen J.
        • Khinast J.
        The future of pharmaceutical manufacturing sciences.
        J Pharm Sci. 2015; 104: 3612-3638
        • Harmonisation TICo
        Q8 (R2) Pharmaceutical Development. In Harmonisation TICo, Editor.
        2009 (Anonymous Internation Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use)